Nektar Therapeutics (NASDAQ: NKTR) was a big winner in 2025. The clinical-stage biotech saw its shares soar on positive clinical developments. Let's give credit where credit is due. Nektar's ...
Nektar Therapeutics produced strong phase 2b data for rezpegaldesleukin in treating eczema this year. That's a vast market where some of the world's best-selling drugs compete, including Dupixent and ...
Nektar Therapeutics has a promising lead drug candidate, but there is considerable risk involved. Madrigal Pharmaceuticals is generating strong revenue from a medicine with significant prospects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results